§ Plasma-derived IVIG

Anti-Cytomegalovirus Intravenous Immunoglobulin (Anti-CMV IVIG) Cytomegalovirus (CMV) is a common virus belongs to a member of the herpes virus family. Due to the prevalence of this virus, most people are likely to be infected at some time during their lives but rarely cause obvious illness; severe complications could happen for immune-compromised people such as organ transplant patients, also for new born infants through congenital or perinatal infection. Anti-CMV IVIG product in combination with anti-viral drug has been used effectively in treating the CMV infection. Based on its plasma process platform technology, Blue Blood had been devoting significant effort developing this product for Taiwan since its inception; and more recently, in working with Prometic BioTherapeutics, Blue Blood is expanding its effort to include anti-CMV IVIG product for world-wide market.